Hydrogel formulations and methods and devices for focal administration of the same
Provided are formulations, methods, and devices for providing a hydrogel. The formulations and resulting hydrogels may be used for treating various disorders, including ocular disorders. In certain embodiments, the hydrogel is formed from formulations comprising (a) a nucleo-functional polymer that is a biocompatible polyalkylene polymer substituted by (i) a plurality of —OH groups, (ii) a plurality of thio-functional groups —R 1 —SH wherein R 1 is an ester-containing linker, and (iii) optionally one or more —OC(O)—(C 1 -C 6 alkyl) groups, such as a thiolated poly(vinyl alcohol) polymer; (b) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups; and (c) one or more pharmaceutically active agents. In certain embodiments, the hydrogel is formed at a targeted sited using methods and/or devices for focal administration of the formulations and/or hydrogels described herein.
1. An injectable, ocular formulation for forming a hydrogel in an eye of a subject, the formulation comprising:
a. a nucleo-functional polymer that is a biocompatible polymer comprising poly(vinyl alcohol) containing a plurality of thio-functional groups —R 1 —SH , wherein —R 1 —SH is —OC(O)—(C 1 -C 6 alkylene)—SH;
b. an electro-functional polymer that is a biocompatible polymer comprising poly(ethylene glycol) containing at least one thiol-reactive group; and
c. a liquid pharmaceutically acceptable carrier comprising 5×phosphate buffered saline (PBS) that is suitable for administration of the ocular formulation to the eye of the subject;
wherein the ocular formulation has a pH in the range of about 7.1 to about 7.7, an osmolality in the range of about 280 mOsm/kg to about 320 mOsm/kg and the formulation forms a hydrogel in the eye of the subject.
2. The formulation of claim 1 , wherein a first solution comprising the nucleo-functional polymer and a second solution comprising the electro-functional polymer are mixed to form the formulation.
3. The formulation of claim 1 , wherein the 5×PBS comprises about 50 mM to about 90 mM sodium chloride, about 2.5 mM to about 3 mM potassium, about 50 mM sodium phosphate, about 9 nM potassium phosphate, or combinations thereof.
4. The formulation of claim 1 , wherein the formulation has an osmolality in the range of about 280 mOsm/kg to about 300 mOsm/kg.
5. The formulation of claim 1 , wherein the formulation has an osmolality in the range of about 300 mOsm/kg to about 320 mOsm/kg.
6. The formulation of claim 2 , wherein the formulation has a viscosity of between about 550 cP and about 1350 cP at around 12-13 minutes after mixing the first and second solutions to form the formulation, or after about 30 seconds to about 120 seconds after mixing when heat is applied to the formulation.
7. The formulation of claim 2 , wherein the formulation has a viscosity of between about 8900 cP and about 11,600 cP at around 17-18 minutes after mixing the first and second solutions to form the formulation, or after about 30 seconds to about 120 seconds after mixing when heat is applied to the formulation.
8. The formulation of claim 2 , wherein the formulation has an initial, low viscosity after mixing the first and second solutions to form the formulation such that the formulation can be administered through a needle having a gauge of less than or equal to 23 using a force of no more than 5 N.
9. The formulation of claim 1 , wherein the formulation is formed following separate injection of the nucleo-functional polymer and the electro-functional polymer into the vitreous cavity of the eye of the subject.
10. The formulation of claim 1 , wherein the nucleo-functional polymer, the electro-functional polymer, or both, are reconstituted in 5×PBS.
11. The formulation of claim 10 , wherein the reconstituted nucleo-functional polymer, the reconstituted electro-functional polymer, or both, has a pH between about 7.1 to about 7.7.
12. The formulation of claim 10 , wherein the nucleo-functional polymer, the electro-functional polymer, or both, are reconstituted after having been stored for at least 1 week, at least 1 month, at least 2 months, at least 6 months, at least 12 months, at least 15 months, at least 18 months, at least 20 months, or at least 24 months.
13. The formulation of claim 1 , wherein the poly(ethylene glycol) is linear, branched, a dendrimer, or multi-armed.
14. The formulation of claim 1 , wherein the hydrogel formed in the eye of the subject undergoes complete biodegradation from the eye of the subject within about 3 days to about 7 days, about 2 weeks to about 8 weeks, about 4 months to about 6 months, or within 12 months or 24 months.
15. The formulation of claim 1 , wherein the hydrogel formed in the eye of the subject results in a pressure within the eye of less than about 30 mmHg.